In non–small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations, the efficacy of atezolizumab‐bevacizumab‐carboplatin‐paclitaxel (ABCP) therapy and platinum‐based chemotherapy after EGFR‐tyrosine kinase inhibitor was found to be equivalent in real‐world setting. Here, EGFR is linked to lung cancer.